#ISPOREurope: Make sure to stop by our booth #C3-077 to meet with our RWE team. Hope to see you there ISPOR! shyftanalytics.com/shyft-ispor-eu/ #RWE #pharma #lifesciences #Meetus

#ISPOREurope: Join our #posterpresentation at ISPOR as our industry experts discuss using 3C-HF prognostic score tool to predict worsening cardiac function among patients. shyftanalytics.com/shyft-ispor-eu/ #PatientsFirst #HeartDisease #clinicaltrials #pharma

#ISPOREurope: another great #posterpresentation at ISPOR to discuss treatment patterns and injectable multiple sclerosis disease shyftanalytics.com/shyft-ispor-eu/ #PatientsFirst #multiplesclerosis #clinicaltrials #pharma

#ISPOREurope: Join our #posterpresentation at ISPOR as we talk about patterns and prediction for cognitive decline in Alzheimer's patients shyftanalytics.com/shyft-ispor-eu/ #PatientsFirst #Alzheirmers #clinicaltrials #pharma

Day 1 at #ISPOREurope: Make sure to stop by our booth #C3-077 to meet with our RWE team. Hope to see you there ISPOR! shyftanalytics.com/shyft-ispor-eu/ #RWE #pharma #lifesciences #Meetus

#ISPOREurope - Join Josh Ransom, Ph.D. Head of RWE, Implementation & Innovation at AcornAI ISPOR as he discusses the critical role of next generation testing, #NGT, in #PrecisionMedicine, and how it affects its future needs for growth and expansion. ispor.org/conferences-ed…

#ISPOREurope: Here's one of SHYFT Analytics's poster presentations for today, Nov 4, where we'll discuss: evaluation of missing data imputation strategies in #clinicaltrial and EMR #data using standardized data models. ISPOR bit.ly/2NEMmBd

Yesterday at #isporeurope our team presented 4 posters. Be sure to visit us during our remaining 3 poster sessions this week. #isporeurope #rwe

Download our #whitepaper to see how #biopharma companies are turning to RWE to provide enterprise value across both clinical and commercial use cases while driving increased time and cost efficiencies>>> shyftanalytics.com/whitepapers/th… #pharma #lifesciences #RWE

#ICYMI - Watch our latest on-demand #webinar as SHYFT's subject matter experts discuss how #data and #analytics can be used to gain a competitive edge when it comes to maximizing brand value and exceeding peak year sales. pages.questexweb.com/SHYFTAnalytics… #pharma #lifesciences

It's not a surprise that the need for #RWE is growing in #biopharma. Studies show that the global market will see a 15% annual growth rate from 2019-2024. We have conducted our own research to see how biopharmas are handling the current state of RWE. shyftanalytics.com/the-current-st…

#OnDemandWebinar: Tune in to hear our experts discuss how the use of #technology can be leveraged to enable the standardization, transparency, & replicability of #RWD research. Download here: pages.questexweb.com/SHYFTAnalytics…

Wishing our customers, partners, staff and their families a very happy thanksgiving 🦃🍁🍂 #HappyThanksgiving

The State of #RWE: Research reveals that RWE has shown immense value for companies that have invested the resources to track, measure, and apply it meaningfully. Here are some more interesting facts: shyftanalytics.com #Data #lifesciences #clinicaltrials #Clinicalresearch

As #lifescience organizations turn data into insights & insights into improved patient outcomes, the roles of CIO & CTO are evolving. Our CIO Rama Kondru is now #CTO too. Watch an interview with him on why that matters for #healthcare: bit.ly/2kTkW0b #DigitalInovation

Download our #whitepaper to see how #biopharma companies are turning to RWE to provide enterprise value across both clinical and commercial use cases while driving increased time and cost efficiencies>>> shyftanalytics.com/whitepapers/th… #pharma #lifesciences #RWE

We were lucky enough to have Nancy Frates at Medidata NEXT a couple years ago. The incredible impact of advocates like Pete Frates on the advancement of science and medicine is something to cherish, and always -- albeit sadly in this moment -- remember. youtu.be/J6912QVIVVc

#Webinar: Does your org struggle when it comes to the FDA + other competent authorities? Join in plain sight as she highlights the key advantages of meeting with the #FDA early in the process to set your #roadmap to success. Reg today: bit.ly/2nYPr6u #clinicaltrials

SHYFT Analytics will officially adopt the Acorn AI, by Medidata brand. The innovative commercial + #dataanalytics tech + services valued by SHYFT customers will operate as the Commercial Data Solutions (CDS) team at Acorn AI. Learn more: bit.ly/32ex1hY #clinicaltrials

Watch Bruno Lempernesse, SVP & GM, Commercial Data Solutions, Acorn AI, talk about SHYFT Analytics adopt the Acorn AI brand & how this will further advance our mission of accelerating the delivery of actionable insights, from molecule to commercialization bit.ly/2Yg47gk